Insilico Medicine, founded 2014 and headquartered in Hong Kong with US operations, runs the Pharma.AI end-to-end AI drug discovery platform spanning target identification, molecule generation, and clinical trial design. The company became the first to publish a peer-reviewed Phase IIa result for a drug where both the target and the compound were identified by generative AI (not a human chemist using AI as a tool). Rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis, produced +98.4 mL mean FVC improvement over 71 patients at the 60 mg once-daily dose against a -20.3 mL placebo decline; the result published in Nature Medicine in 2025.
The company's commercial story accelerated in 2026. The June 22 BIO 2026 opening-day pact with SK Biopharmaceuticals committed up to $2.5 billion in potential value ($18 million upfront, $670 million in development and commercial milestones per program) across an AI-driven neuroimmune drug discovery collaboration. The pact sits alongside Insilico's earlier work with Lilly (Insilico-Lilly $2.75B AI deal in 2022-2023) and validates the Pharma.AI platform across multiple pharma partners. INS018_055 (the original Rentosertib designation) is moving toward Phase 3 in IPF in H2 2026, with INS019_039 (oncology) and additional pipeline assets at IND-stage.
STAT News' BIO 2026 closing coverage cited Rentosertib as the proof point that AI drug discovery moved 'from investment thesis to clinical fact.' Stories tagged here cover Insilico pipeline updates, partnership deals, and the broader AI drug discovery thread. See [[ai-drug-discovery]], [[sk-biopharmaceuticals]], [[rentosertib]], and [[china]] for adjacent threads.
Network Bio launched Thursday August 20, 2026 with $50 million in Series A financing. Company thesis: build AI models trained on human biological data (spanning multi-omics, single-cell sequencing, and functional genomics datasets) for drug discovery across multiple therapeutic areas. The launch adds to the rapidly expanding AI-driven peptide and biologic discovery ecosystem that also includes PeptiDream's PDPS platform (Kawasaki-based, constrained cyclic peptide focus with active partnerships across Novartis, Merck, Genentech/Roche, AbbVie, Bristol Myers Squibb, and Eli Lilly), Insilico Medicine's Pharma.AI (31 developmental candidates on the platform, $2.75 billion Lilly collaboration March 2026, $2.5 billion SK Biopharmaceuticals deal June 2026, Takeda strategic collaboration July 2026), Aizen Therapeutics' DaX foundation model (August 15 deal with San Diego public biotech worth up to $100 million per target for oral peptide therapeutics, non-canonical amino acid chemical space at 10x traditional scale), and Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling for target validation and small-molecule design). The AI drug discovery category has accumulated more than $8 billion in partnership deal value across 2026 to date, with peptide-focused platforms capturing a substantial share of the total given the growth of the peptide therapeutic modality across obesity (GLP-1 class), rare disease (setmelanotide, palopegteriparatide, vosoritide, avexitide), and oncology (peptide-drug conjugates, radioligand therapies). Network Bio's Palo Alto location adds to the West Coast AI biotech cluster that also includes Recursion, Insitro, and Isomorphic Labs.
Aizen Therapeutics announced a multi-program collaboration with a San Diego-based public biotech to design oral peptide therapeutics using its DaX foundation model. Deal terms: several million dollars in initial revenue plus up to $100 million in milestones for each nominated target. The collaboration will develop proof of activity with the DaX platform for well-known disease-relevant targets in immunology and neurology indications, with the potential to expand the roster of targets over time. The DaX platform has been trained on millions of uniquely annotated molecules and receptors and explores the non-canonical amino acid (ncAA) peptide chemical space at 10x the scale of traditional ncAA discovery methods. Non-canonical amino acids extend beyond the standard 20 natural amino acids to include modified building blocks that give peptides properties (metabolic stability, membrane permeability, oral bioavailability) that natural peptides do not have; this is essential for the oral peptide therapeutics that the collaboration targets. DaX positions Aizen as one of the more substantial AI-driven peptide discovery platforms alongside PeptiDream's PDPS system (Kawasaki-based, constrained cyclic peptide focus with active collaborations across Novartis, Merck, Genentech, AbbVie, and Eli Lilly), Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling), and Insilico Medicine's Pharma.AI (which has secured over $5 billion in partnership deal value across 2026). The collaboration adds to the growing evidence that AI-designed peptides are becoming a distinct drug discovery category with real deal-flow.
BioSpace published a feature on August 12, 2026 profiling Insilico Medicine CEO Alex Zhavoronkov, synthesizing a running theme across 2026: the AI-native drug discovery platform has crossed the threshold from software vendor to pipeline sponsor. Insilico now has 31 developmental candidates on its Pharma.AI platform (which spans target validation, generative chemistry, and molecule optimization for target-to-candidate discovery). The 2026 partnership deal tally includes the March 2026 Eli Lilly collaboration granting Lilly an exclusive worldwide license to a portfolio of preclinical oral therapeutics with Insilico eligible for up to $2.75 billion in payments plus tiered royalties, the June 2026 SK Biopharmaceuticals deal worth more than $2.5 billion for neuroimmune conditions development, and the July 2026 Takeda strategic collaboration across multiple therapeutic areas. Insilico also completed a $110 million financing round earlier in 2026 to advance its platform and pipeline. The pipeline itself includes peptide, small molecule, and biologic candidates across oncology, fibrosis, and metabolic indications. The story extends the broader debate on whether AI-assisted drug discovery is a substantial productivity shift or an incremental improvement over existing chemoinformatics and structural biology tools; Insilico's deal-flow record is one of the strongest empirical arguments on the substantial-shift side of that debate.
STAT News' Pharmalittle column on Tuesday June 30, 2026 disclosed that US lawmakers are investigating whether several large pharmaceutical companies have been involved in clinical trials at Chinese sites that helped advance China's military capability. The investigation runs parallel to the BIOSECURE Act (passed 2024) restricting US biotech contracting with named Chinese CDMOs and gene-sequencing companies, and to the structural anxiety about Chinese scientific output that biotech executives flagged at BIO 2026 last week. The Insilico Medicine (Hong Kong-headquartered) + SK Biopharmaceuticals $2.5 billion AI-neuroimmune drug discovery pact announced June 22 at BIO 2026 opening sits inside this conversation, as do Chinese-API supply chains feeding US gray-market peptide vendors and the licensed-generic semaglutide flow from Indian and Chinese manufacturers post-March 2026 patent expiration. The lawmaker probe expands the regulatory aperture beyond the BIOSECURE Act's named-entity list toward broader scrutiny of US-China clinical-research cooperation. No specific drugmakers were publicly named in the Pharmalittle report.
STAT News' closing coverage of BIO 2026 in San Diego across two pieces, Alex Hogan's June 26 STATus Report and Damian Garde's June 25 key-takeaways feature, identified two organizing themes that emerged from the four-day convention. First, AI drug discovery shifted from investment-thesis territory to clinical-fact territory: Insilico Medicine's rentosertib (a TNIK inhibitor for idiopathic pulmonary fibrosis where both the target and the compound were identified by generative AI, not a human chemist) became the first peer-reviewed Phase IIa result for a fully AI-discovered drug when results were published in Nature Medicine in 2025 (60 mg once daily produced +98.4 mL mean FVC change versus -20.3 mL placebo across 71 patients). Second, biotech executives at BIO 2026 expressed structural anxiety about Chinese drug development that the industry's primary legislative response, the BIOSECURE Act, does not address: the concern is about the speed and depth of Chinese scientific output rather than about narrow IP or supply-chain risks. The convention's mood reportedly shifted notably from the depressed atmosphere at industry events in 2024-2025 (when capital markets were closed and FDA reviewer turnover was concerning) toward a more constructive engagement with the new operational reality.
The 2026 BIO International Convention closed Thursday June 25 at the San Diego Convention Center after four days, 20,000+ industry leaders in attendance, 130+ sessions across 18 focus areas, and a partnering-meeting volume that BIO sources said matched or exceeded prior-year records. Peptide-relevant headline deals across the convention week: the Insilico Medicine + SK Biopharmaceuticals $2.5 billion AI-neuroimmune drug discovery deal on Day 1 (June 22, $18M upfront + $670M per program in development and commercial milestones); BioArctic + Eli Lilly $800 million BrainTransporter blood-brain barrier delivery pact on Day 2 (June 23); STAT News' Day-3 BIO Readout column behind-the-scenes coverage of Eli Lilly's January Chai Discovery AI biologics partnership (June 24); and the disclosed Lilly-Astellas joint stalking-horse bid for Sangamo Therapeutics assets in bankruptcy (capsid delivery platform, zinc finger platform, modular integrase platform, prion disease program ST-506; Astellas takes Fabry disease asset isaralgagene civaparvovec). Fujifilm Life Sciences showcased a continuous electroporation gene delivery system and high-sensitivity in-line Raman measuring system at its Innovation Showcase. BIO 2027 returns to Boston June 7-10, 2027.
The BIO International Convention opens Monday June 22 in San Diego through Thursday June 25, drawing 20,000+ industry leaders across 130+ sessions in 18 focus areas — the year's largest peptide-and-biopharma deal-making and pipeline conference. Among the opening-day announcements: Insilico Medicine and SK Biopharmaceuticals will formally announce a research and development collaboration to discover AI-enabled innovative drug candidates in the neuroimmune CNS area, with Insilico eligible for up to $18M in upfront and near-term milestone payments and total potential deal value exceeding $2.5B including development, regulatory, and commercial milestones plus single-digit royalties. The pact sets a record for Insilico's APAC partnership totals. Industry watchers will track BIO 2026's deal-making cadence as the post-ADA / post-ENDO cycle concludes and the FDA PCAC peptide-compounding decision (July 23-24) becomes the next major regulatory catalyst.